Images List Premium Download Classic

Vaccine Adjuvant

Vaccine Adjuvant-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Pyrazolopyrimidine compounds
October 12, 2017 - N°20170290910

Wherein r1 is n-c1-6alkyl or c1-2alkoxyc1-2alkyl-, r2 is halo, oh or c1-3alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or 2, are inducers of human interferon. Compounds which induce human interferon may be ...
Recombinant chicken interleukin-1 beta protein for producing antibody early and retaining for a longer period ...
National Tsing Hua University
September 28, 2017 - N°20170275349

The present invention provides a recombinant chicken interleukin-1β protein for producing antibody early and retaining for a longer period of time, which has a sequence of seq id no:2 or seq id no:3. The recombinant chicken interleukin-1β protein is created by using point mutation in a genetic engineering method; it can significantly improve the original vaccine ...
Novel peptide and use thereof
Osaka University
September 28, 2017 - N°20170275336

An object of the present invention is to provide a novel peptide and a novel immunostimulant or hair grower containing the peptide as an active ingredient. The present invention provides a peptide of 23 or less amino acids comprising the amino acid sequence lhrlkrlrkrl (seq id no: 1), preferably the amino acid sequence lhrlkrlrkrlk (seq id no: 9), and also provides an immunostimulant ...
Vaccine Adjuvant Patent Pack
Download + patent application PDFs
Vaccine Adjuvant Patent Applications
Download + Vaccine Adjuvant-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Vaccine Adjuvant-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Vaccine adjuvant compositions
Children's Medical Center Corporation
August 10, 2017 - N°20170224811

Embodiments described herein relate to combinatorial compositions and uses thereof, for example, as vaccine adjuvant compositions, for enhancing immune response, for inducing differentiation of nave t cells to differentiate into ifn-γ-producing t cells, and for preventing and treating infections. The combinatorial composition comprises tlr and clr agonists. The combinatorial composition comprises at least one tlr4 agonist and ...
Adjuvanted influenza vaccines for pediatric use
Seqirus Uk Limited
July 20, 2017 - N°20170202955

An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection. The improvement in immune responses is seen for both influenza a ...
Pharmaceutical combinations for immunotherapy
Technische Universitat Dresden
July 06, 2017 - N°20170189522

The present invention relates generally to a method for regulating immune reactions and test substances useful for same. Specifically, the method of the present invention relates to the modulation of the nerve growth factor receptor p75ntr, which is expressed by plasmacytoid dendritic cells. More specifically, the invention relates to a combination comprising at least one modulator of p75ntr ...
Vaccine Adjuvant Patent Pack
Download + patent application PDFs
Vaccine Adjuvant Patent Applications
Download + Vaccine Adjuvant-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Vaccine Adjuvant-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel compounds
3m Innovative Properties Company
June 08, 2017 - N°20170158724

And pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous ...
Vaccine adjuvants
Purdue Research Foundation
May 11, 2017 - N°20170128567

The present invention provides a new adjuvant for administering vaccines.
Novel compounds
Purdue Research Foundation
March 23, 2017 - N°20170080085

Wherein r1 is n-c4-6alkyl or c1-2alkoxyc1-2alkyl-; r2 is hydrogen or methyl; each r3 is hydroxy, halo or n-c1-3alkyl; m is an integer having a value of 2 to 4; n is an integer having a value of 0 to 3; and p is an integer having a value of 0 to 2, are inducers of human interferon. Compounds ...
Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon
Purdue Research Foundation
March 02, 2017 - N°20170057963

Wherein r1 is hydrogen, methyl or —(ch2)2or3, r2 is methyl or —(ch2)2or4, or r1 and r2, together with the nitrogen atom to which they are attached, are linked to form a 5- or 6-membered heterocyclyl wherein the 6-membered heterocyclyl is optionally substituted by two hydroxy substituents; r3 and r4 are each independently hydrogen or methyl; and ...
Vaccine adjuvants for cytomegalovirus prevention and treatment
The Johns Hopkins University
January 26, 2017 - N°20170021014

The present invention relates to the field of virology. More specifically, the present invention provides methods and compositions useful for treating human cytomegalovirus using bacterial cell wall components mdp and tri-dap as vaccine adjuvants. In specific embodiments, the present invention provides a pharmaceutical composition comprising a human cytomegalovirus vaccine and a nod1 activator and/or a nod2 activator. In particular ...
Plasmid, method and kit thereof for producing heat labile enterotoxin b-subunit
Agricultural Technology Research Institute
January 05, 2017 - N°20170002045

The present invention provides a plasmid, method and kit for producing heat labile enterotoxin b-subunit based on a bacillus subtilis expression system. By comparing with the conventional method in the art, the present invention has the advantages of high safety, good yield, and simplified process and is therefore favorable for the commercialization object of heat labile enterotoxin b-subunit in the ...
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
Merck Sharp & Dohme Corp
December 15, 2016 - N°20160361411

The instant invention provides for novel lipid nanoparticle (lnp) formulations, containing cationic lipids, for use as vaccine adjuvants and/or as antigen delivery systems. It is an object of the instant invention to provide lnp formulations that demonstrate enhancements in humoral and cellular immunogenicity of vaccine antigens, particularly subunit vaccine antigens, when utilized alone or in combination with immunostimulatory agents (...
Vaccine Adjuvant Patent Pack
Download + patent application PDFs
Vaccine Adjuvant Patent Applications
Download + Vaccine Adjuvant-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Vaccine Adjuvant-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
National Research Council Canada
October 06, 2016 - N°20160287698

Disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof as an adjuvant for the preparation of an oral vaccine. Further disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof for enhancing the immune response to an orally administered vaccine.
Use of rapamycin as vaccine adjuvant and preparation method therefor
Institut Pasteur Of Shanghai, Chinese Academy Of Sciences
September 29, 2016 - N°20160279236

Disclosed are an immuno-enhancer composition, a use of same as a vaccine adjuvant, and a preparation method therefor. The composition comprises rapamycin and a toll-like receptor agonist-type adjuvant.
6-amino-purin-8-one compounds
Institut Pasteur Of Shanghai, Chinese Academy Of Sciences
August 11, 2016 - N°20160228445

Wherein r1 is c1-6alkylamino, c1-6alkoxy, or c3-7cycloalkyloxy; m is an integer having a value of 3 to 6; n is an integer having a value of 0 to 4; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases ...
1,2,3-triazole-tethered carbohydrate-di and tri lipidated cysteine conjugates useful as vaccine adjuvants and process for preparation ...
Institut Pasteur Of Shanghai, Chinese Academy Of Sciences
July 14, 2016 - N°20160200758

The present invention also provides process for preparation of carbohydrate-di and tri lipidated cysteine based 1,2,3-triazoles. The carbohydrate-di and tri lipidated cysteine based 1,2,3-triazoles as vaccine adjuvants are useful in formulations for therapeutic and prophylactic vaccines against bacterial, viral, protozoan infections and cancer.
Lipidated immune response modifier compound compositions, formulations, and methods
Institut Pasteur Of Shanghai, Chinese Academy Of Sciences
June 23, 2016 - N°20160175433

The compound n-(4-{[4-amino-2-butyl-1h-imidazo[4,5-c]quinolin-1-yl]oxyl}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.
An oil-in-water emulsion containing no surfactant and use thereof
Institut Pasteur Of Shanghai, Chinese Academy Of Sciences
June 23, 2016 - N°20160175432

The present invention discloses an oil-in-water emulsion containing no surfactant, which comprises a metabolizable oil phase, an aqueous phase and oil-water amphipathic solid particles dispersed in the aqueous phase and having biocompatibility, wherein the oil phase comprises squalene or/and tocol; the aqueous phase is any one selected from the group consisting of purified water, water for injection, glycerine aqueous ...
Vaccine system for vaccine adjuvant
Vaxform Llc
May 19, 2016 - N°20160136266

The present invention provides adjuvant compositions that have improved stability, increased potency and which provide an enhanced th1 response. The present invention also provides methods of making those compositions and administration of the improved adjuvant compositions
Composition comprised of antigen linked to a tnf superfamily ligand
Vaxform Llc
May 05, 2016 - N°20160122412

The invention provides fusion proteins comprising antigens of infectious disease agents and cancer cells linked to multiple-trimer forms of tnf superfamily (tnfsf) ligands. The tnfsfs serve as vaccine adjuvants for increasing the immune response to the antigens. In particular, a fusion polypeptide strand that self-assembles inside cells into a multiple-trimer form of cd40 ligand (cd40l, tnfsf5) is provided. Other ...
Loading